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AbstrACt
Introduction Haemophilia is a rare, inherited disorder in 
which blood does not clot normally, resulting in bleeding 
into joints and muscles. Long-term consequence is 
disabling joint pain, stiffness, muscle weakness, atrophy 
and reduced mobility. The purpose of this proposed 
feasibility of a randomised controlled trial (RCT) is to 
test the feasibility of an age-appropriate physiotherapy 
intervention designed to improve muscle strength, posture 
and the way boys use their joints during walking and 
everyday activities.
Methods and analysis A small-scale two-centre 
RCT of a 12-week muscle strengthening exercise 
intervention versus usual care for young children with 
haemophilia will be conducted. Primary outcomes will 
be safety and adherence to the exercise intervention. 
Secondary outcomes will include recruitment, retention 
and adverse event rates, clinical data, muscle strength, 
joint biomechanics and foot loading patterns during 
walking, 6 min timed walk, timed-up-and-down-stairs, 
EQ-5D-Y, participants’ perceptions of the study, training 
requirements and relevant costs. Recruitment, follow-
up, safety and adherence rates will be described as 
percentages. Participant diary and interview data will 
be analysed using a framework analysis. Demographic 
and disease variable distributions will be analysed for 
descriptive purposes and covariant analysis. Estimates 
of differences between treatment arms (adjusted for 
baseline) and 75% and 95% CIs will be calculated.
Ethics and dissemination The study has ethical approval 
from the London—Fulham Research Ethics Committee 
(17/LO/2043) as well as Health Research Authority 
approval. As well as informing the design of the definitive 
trial, results of this study will be presented at local, 
national and international physiotherapy and haemophilia 
meetings as well as manuscripts submitted to peer-
reviewed journals. We will also share the main findings of 
the study to all participants and the Haemophilia Society.
IntroduCtIon
Haemophilia is a rare, inherited disorder 
in which blood does not clot normally. 
Repeated spontaneous and traumatic 
bleeding into joints and muscles is the result; 
the ankle joint being the most common.1 
Long-term consequence is chronic arthrop-
athy, a pattern of disabling joint pain, stiff-
ness, muscle weakness, atrophy and reduced 
mobility.2–4 The introduction of prophylaxis 
with clotting factor concentrates has reduced 
the number of bleeding episodes experi-
enced by children, changing their lifestyle 
and long-term outlook.5 6 However, evidence 
indicates that despite prophylaxis, boys still 
bleed one to two times per year, with rela-
tively few bleeding episodes being required to 
initiate bone destruction, and in some cases, 
articular erosion is evident with no history of 
joint bleeding.1 7–9 Furthermore, children are 
more susceptible to blood-induced damage 
than adults and once established is progres-
sive and irreversible.10 
It is well established that muscle weakness 
is associated with haemophilic arthropathy 
in adults,4 and it is now becoming apparent 
that muscle strength is reduced in children, 
strengths and limitations of this study
 ► This study investigates the feasibility of a mul-
ticentre randomised controlled trial of a muscle 
strengthening exercise intervention versus usual 
care in children with haemophilia.
 ► The intervention to be studied has been coproduced 
by children with haemophilia, their parents and 
healthcare professionals.
 ► It is impossible to blind those in receipt and those 
delivering the intervention as to the group allocation, 
but we will blind the assessor as to group allocation.
 ► At the end of this study, we will not be able to an-
swer the question ‘Does exercises help improve the 
long term health of children with haemophilia?’, but 
we will know whether such a study could be under-
taken and the best way to deliver the intervention.
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prior to the onset of clinical arthropathy.11 In a study of 
10 adolescent and adult haemophiliacs with a history of 
unilateral knee bleeding, Falk et al found that strength of 
the knee extensors and flexors in haemophilic children 
was significantly weaker than those of the age-matched 
controls.12 13 More recently, Stephensen et al observed 
that despite normal clinical examinations and compa-
rable levels of physical activity, young haemophilic boys 
with a history of ankle joint haemorrhage had signifi-
cantly reduced dynamic muscle strength together with 
atrophy of the knee extensors, ankle dorsiflexors and 
plantarflexors when compared with age-matched and 
size-matched typically developing peers.11 Furthermore, 
muscle weakness of the leg is strongly correlated to muscle 
atrophy, reduced walking distances, slower ascent and 
descent of stairs, as well as reduced ankle joint motion, 
greater knee flexion motion and forces at the knee and 
ankle joint during walking.14 15
Therapeutic exercise is an important component of the 
management of other forms of arthropathy (eg, osteo-
arthritis, rheumatoid arthritis),16 and it would appear 
logical that exercise would be effective for people with 
haemophilia. There is growing evidence of the benefits 
of incorporating muscle strengthening exercise in their 
management of arthropathy.17 It is the view of clinicians 
that increases in muscular strength and postural control 
might improve motor performance and cardiovascular 
fitness, limit exaggerated end-range joint movement 
and promote optimal transfer of weight-bearing forces 
through joints, thereby minimising muscle imbalance, 
synovial impingement and associated haemarthroses 
or synovitis.18 However, there is a lack of evidence to 
support these assumptions. A recent Cochrane Review 
evaluating the safety and effectiveness of exercise for 
people with haemophilia reported four randomly 
controlled studies of an exercise intervention in children 
with the condition and concluded the studies were of low 
or very low quality, due to small sample sizes and poten-
tial bias.17 Furthermore, no paediatric study compared 
a muscle strengthening intervention to a control group 
or intervention without muscle strengthening exercises. 
Several studies compared two multicomponent exercise 
interventions that included broad muscle strengthening 
as well as treadmill walking and cycle ergometry, and it is 
not possible to determine the effect of muscle strength-
ening on muscle strength or its effect on physical func-
tion.19 20 Furthermore, preadolescent and adolescent 
boys aged between 10 and 14 years were included in these 
studies, and it is not known if the groups were matched 
for pubertal status.
Despite the apparent benefit, there is a lack of robust 
evidence to determine whether muscle strengthening 
exercise can improve or negatively affect outcomes for 
young children with haemophilia. The purpose of this 
proposed feasibility RCT is to test the feasibility of an 
age-appropriate physiotherapy intervention designed to 
improve muscle strength, posture and the way boys use 
their joints during walking and everyday activities.
MEthods And AnAlysIs
The protocol version for this feasibility study is 
V.2—19 December 2017. The Standard Protocol Items: 
Recommendations for Interventional Trials (SPIRIT) 
guidelines21 have been used to report the study protocol.
Participants
Participants will be invited from two haemophilia centres. 
Twenty boys with severe or moderate haemophilia A or 
B with or without inhibitors on prophylactic treatment 
with coagulation factor concentrate, aged 6–11 years, 
will be recruited. Boys with or without symptoms of joint 
damage (evaluated using the Haemophilia Joint Health 
Score and Haemophilia Early Arthropathy Detection 
with Ultrasound score) will be eligible to participate. 
Exclusion criteria are as follows: von Willebrand disease, 
history of fracture or trauma to the lower limb, ortho-
paedic surgery, acquired brain injury or any other distur-
bance of the central nervous system, joint or muscle 
bleed in the lower limb in the past 6 weeks, presence 
of lower limb pain or unable to fully comply with verbal 
instructions.
Participants will be identified from each Haemophilia 
Centre’s database of registered patients. The parents 
or guardians of eligible participants will be approached 
initially by the principle investigator at each site via 
telephone to provide a brief verbal explanation of the 
research study and ask if they would be happy to receive 
a patient information sheet. Should they be interested in 
participating in the study they will receive, by post, the 
patient information sheet (one for parents and a sepa-
rate age-appropriate version for children) at least 1 week 
prior to their next clinic appointment. This will allow for 
a ‘cooling-off’ period of a minimum of 1 week for the 
potential participants. The researcher will then be avail-
able for questions by telephone or at the participant’s 
next clinic appointment.
At their clinic appointment, the investigator will 
meet with the participant and parent/legal guardian to 
complete the consent form as appropriate. The inves-
tigator will further explain the study procedures, why 
they are being asked to consider including their child in 
this study and the associated risks and benefits of being 
included. They will then be given an opportunity to ask 
any further questions. The child/parent/ legal guardian 
will then be asked to confirm if the potential participant 
agrees to take part in the study. If consent is agreed, a 
parental consent form will be completed by the parent/
guardian and a copy will be provided. If at any point 
during the study process the parent/guardian does not 
consent to inclusion in the study, then any data collected 
will be destroyed. Any decision to refuse or withdraw 
from the study will in no way influence the services that 
they receive. Once the child’s parent/guardian has given 
consent, the child must also indicate that they do not 
object to participating in the research activity. This partic-
ipant ‘assent’ will be sought.
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study design
Following written informed consent and screening of 
eligibility criteria, randomisation of eligible participants 
for the study will be performed with the online rando-
misation service http:// sealedenvelope. com/. Utilising 
the secure, centralised and independent service, partic-
ipants will be randomly allocated into one of the two 
groups (treatment group 1 will receive a 12-week muscle 
strengthening exercise intervention; treatment group 
2 will receive usual physiotherapy care for 12 weeks) 
on a ratio of 1:1. Allocation will be stratified by centre 
to ensure the same numbers of participants at each site 
are allocated to the two groups. The unblinded principal 
investigator at each site will be issued with a password to 
access the service to create a new randomisation for the 
study participants. Those allocated to treatment group 2 
will be offered the intervention after their end of study 
follow-up assessment. Data will be collected prior to and 
immediately postintervention (figure 1).
It is impossible to blind those in receipt and those 
delivering the intervention as to the group allocation. 
However, it will be possible—although perhaps chal-
lenging—to blind the assessor as to group allocation. 
Consequently, we will attempt a single blind approach 
in which the participant and physiotherapists delivering 
the intervention will be encouraged to withhold their 
group allocation from the assessors collecting data. We 
will use a range of strategies, including instruction in the 
participant literature, intervention protocol and with 
frequent verbal prompts. In order to assess the efficacy of 
blinding, we will ask assessors to record which group they 
think participants have been allocated to at the end of 
each assessment. This will be presented as a binary forced 
choice. There are no circumstances under which it would 
be necessary to unblind assessors.
Intervention
The intervention developed by expert clinicians and 
patients utilising a modified Nominal Group Technique 
(NGT) is a 24-session, 12-week programme designed as 
2-week progressive levels (intensity and or load) with no 
more than 10 exercises in each session, taking 25–30 min 
to complete (figure 2). The intervention aims to master 
movement control and emphasises body-weight strength 
development. Pictures of the exercises and instructions 
for each phase will be provided in 2-week exercise diaries. 
Participants will be asked to complete the exercises twice 
per week; once with the physiotherapist who will visit the 
participant at home and once supervised by their parents/
guardian. Completion of exercises, along with treatment 
regimen, any adverse events and comments in relation 
to the exercise programme will be recorded in the exer-
cise diary. They will also record participation in physical 
activities, including type, time and intensity. According to 
predetermined criteria (safe and competent), the physio-
therapist will determine if it is appropriate for the partic-
ipant to progress to the next exercise level. On return 
of the exercise diary every 2 weeks, participants will be 
provided with a gift voucher.
usual care
Participants will continue to receive their usual care as 
recommended and prescribed by the haematologist, phys-
iotherapist and other members of the healthcare team. 
This will include factor concentrate treatment, any phys-
iotherapy or surgical intervention or advice that is recom-
mended by the clinical care team. There are currently no 
standardised treatment recommendations for children 
without apparent joint damage. The researchers will not 
make or initiate any changes to routine treatment. Any 
change to or initiation of new treatment or intervention 
Figure 1 Flowchart of participant journey through the 
feasibility study. ABR, annualised bleeding rate; HEAD-
US, Haemophilia Early Arthropathy Detection with 
Ultrasound; HJHS, Haemophilia Joint Health Score; TUDS, 
timed-up-and-down-stairs; 6MWT, 6-minute timed walk. 
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will be recorded and the treating clinician will determine 
whether it is appropriate for the participant to continue 
in the study. Participants will be provided with a diary to 
record participation in physical activities, including type, 
time and intensity. Participants will be telephoned weekly 
to encourage dairy completion. On return of the diary 
every 2 weeks, participants will be provided with a gift 
voucher.
outcome measures
Primary outcome measures are as follows:
 ► Safety will be evaluated using annualised bleeding 
rates, coagulation factor usage (what the patient 
actually administers and records on their routine 
electronic diary) and reported adverse events and 
reactions associated with the intervention. Association 
with symptoms of joint disease (Haemophilia Joint 
Health Score and Haemophilia Early Arthropathy 
Detection with Ultrasound score) will be evaluated.
 ► Adherence to the exercise intervention will be evalu-
ated by the number of exercise session completed as 
a percentage of the prescribed exercise sessions. Data 
will be extracted from participant diaries.
Secondary outcome measures are as follows:
 ► Recruitment rate determined as the participants who 
volunteer to participate in the study as a percentage of 
those that are invited/eligible.
 ► Willingness to be randomised; evaluated at the end of 
study through semistructured interviews that will be 
audio-recorded and be transcribed by a member of 
the research team.
 ► Participant’s acceptability of the trial and interven-
tion: using semistructured interviews, conducted 
at the completion of the study, the participants will 
be asked their views on acceptability of the trial and 
intervention, recruitment and exercise adherence. 
The interview will be audio-recorded and transcribed 
by a member of the research team.
 ► Training required to deliver the intervention and 
collect outcome data at study visits: using semistruc-
tured interviews, conducted at the completion of 
the study, the physiotherapists will be asked their 
views on acceptability of the trial and intervention, 
recruitment and exercise adherence. They will also 
be asked about the training requirements for deliv-
ering the intervention as well as the appropriateness 
of the outcomes piloted in terms of training, length of 
time to complete and clinical value of the data. The 
interview will be audio-recorded and transcribed by a 
member of the research team.
 ► Haemophilia Joint Health Score (HJHS)—a clinical 
examination of swelling, muscle atrophy, strength, 
joint crepitus, range of motion and pain at the ankle, 
knee and elbow joints. The HJHS is a standardised 
multi-item assessment, currently used in clinic as part 
of routine care to record musculoskeletal health.22
 ► Haemophilic synovitis and arthropathy—the pres-
ence and severity of signs of haemophilic synovitis and 
arthropathy will be evaluated using the Haemophilia 
Early Arthropathy Detection with Ultrasound (HEAD-
US) score. The HEAD-US protocol is a standardised 
Figure 2 Description of the exercise intervention.
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scanning protocol used to identify the presence and 
severity of synovitis, articular cartilage and chondral 
bone defects in the ankle, knee and elbow joint. The 
scanning procedure takes approximately 2–3 min per 
joint and we have recently shown good inter-rater 
repeatability of this protocol when performed by 
physiotherapists.23 24
 ► Muscle strength of the knee extensors and ankle 
dorsiflexors and plantarflexors—maximum torque 
will be recorded with a hand-held dynamometer 
(Manual Muscle Tester, Lafayette Instrument, USA) 
using our standardised protocol with excellent test-re-
test repeatability.15
 ► Joint biomechanics and motion during walking—
temporal spatial and three-dimensional (3D) joint 
motion during gait will be recorded using an inertial 
magnetic measurement gait analysis system (MVN 
BIOMECH Awinda, Xsens Technologies, Nether-
lands). Sensor units will be attached to the feet, lower 
legs, thighs and pelvis with elastic straps. Motion of 
the sensors will be used to calculate temporal spatial 
and 3D lower limb joint motion.
 ► Static and dynamic foot loading patterns—will be 
evaluated with a plantar pressure platform (HR Mat, 
Tekscan, USA). Centre of pressure motion in respect 
of distance and direction travelled, together with 
contact time as a measure of foot symmetry of foot 
loading for various foot segments (heel, midfoot and 
forefoot) along with distribution of peak pressure and 
pressure-time integrals will be evaluated.
 ► Six min timed walk—distance walked in 6 min. Two 
marker cones will be placed 30 m apart along a 
corridor and each subject will be asked to walk back 
and forth between the cones as fast as they can for 
6 min.15
 ► Timed-up-and-down-stairs—time taken to ascend and 
descend a flight of 12 steps. The children will stand 
30 cm from the bottom step and asked to walk quickly 
but safely up the stairs, turn around on the top step 
and come all the way down until both feet land on the 
bottom step. They will be instructed to step on every 
step, use the hand rail if they want and not to run.15
 ► EQ-5D-Y—a five dimension (mobility, self-care, usual 
activities, pain/discomfort, anxiety/depression) ques-
tionnaire measuring health-related quality of life.25
 ► Costs relevant to the study—intervention costs, 
health and social care costs, out-of-pocket expenses 
and time off work costs. Healthcare costs (using 
National Health Service reference costs were 
possible) will include training and delivering the 
intervention, equipment, overhead costs, visits to 
hospital/haemophilia clinic, general practitioner, 
other healthcare services, investigations, hospitalisa-
tion, treatment, coagulation clotting factor concen-
trate and medication. Patient and family costs will 
include travel and time off work. Feasibility of 
collecting these data will be explored along with the 
resource consequences.
Data will be collected at the respective haemophilia 
centres. All data collected related to the study will be 
confidential and anonymous. The participant will be 
allocated a randomised participant number code, and all 
data collected will relate to this code. A record of which 
code belongs to which subject will be stored in a locked 
cabinet separate from the study data. Only the principle 
investigator (who will be a member of the participant’s 
direct care team) will have access to this documentation. 
The direct care team and the principal investigator will 
have access to participant’s personal and identifiable 
information during the study. Consent will be sought by 
the lead researcher for the research team to have access 
to this personal information.
Analysis methods
Recruitment, follow-up, safety and adherence rates will 
be described as percentages. Participant diary and inter-
view data will be analysed to identify factors that influence 
these rates and acceptability of the trial using a frame-
work analysis. Interview data from physiotherapists will be 
analysed using a framework analysis to determine training 
required to deliver the intervention and collect outcome 
data. Feasibility of collecting healthcare cost data will be 
explored along with the resource consequences. Costs 
will be analysed and reported using descriptive statistics. 
Demographic and disease variable distributions will be 
analysed for descriptive purposes and covariant anal-
ysis. Walking variables will be normalised to leg length 
and muscle strength to body mass. Group mean and SD 
(median and interquartile range where appropriate) will 
be calculated and reported. Change from baseline data 
will be compared between groups at all study time points 
using analysis of covariance with baseline as a covariate 
and a factor for centre. Estimates of differences between 
treatment arms in the changes from baseline (adjusted 
for baseline) and 75% and 95% CIs will be calculated. 
Group mean and SD (median and interquartile range 
where appropriate) will be calculated preintervention 
and postintervention. These data will allow us to estimate 
the potential effect of the intervention and provide esti-
mates of variability to inform the sample size required for 
a full RCT, as well as to refine the outcome measures by 
evaluating their responsiveness to changes in musculo-
skeletal health.
Patient and public involvement
Ten specialist haemophilia physiotherapists in the UK plus 
those experienced in sports injury were invited to take 
part in an NGT consensus discussion to share their expe-
rience and expertise to contribute to the development of 
the exercise intervention. Patients’ priorities, experience 
and preferences informed the study design, recruitment 
as well as the design and delivery of the intervention. 
The exercise programme was demonstrated to five boys 
with haemophilia and their parents who were members 
of the Haemophilia Society, National UK Patient Organ-
isation. The parents and children were asked about what 
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they thought about the exercises and whether they could 
undertake them on a regular basis, where they thought 
the best place was for undertaking them and how they 
would like to receive the information on the exercise 
programme. Parents and children were then asked ques-
tions about how they would feel about taking part in study 
testing the benefits of the exercises, issues around being 
allocated randomly into study groups and then questions 
about what would encourage the children to continue 
on the exercise programme with discussions focusing on 
types of rewards and incentivisation.
Management and oversight of the study
East Kent Hospital University Foundation Trust is the study 
sponsor. They have overall responsibility for governance 
of the study and have no direct role in study design, data 
collection, management, analysis, interpretation of data 
and reports and publications that arise from the study.
A Research Monitoring Committee (RMC) has been 
established and will meet 6 monthly after the study has 
commenced. The RMC will be responsible for moni-
toring milestones and targets, data, safety, recruitment, 
reviewing and interpreting the results. The RMC will 
be chaired by an independent chair from outside the 
research team group. Additional meetings may be called 
to review any serious adverse events, adverse events (AEs) 
and adverse reactions (ARs). The chief investigator will 
co-ordinate day to day running of the research, complete 
ethical approvals, communicate with recruitment sites, 
complete training of physiotherapists to deliver the inter-
vention, undertake research initiation and monitoring 
site visits, co-ordinate data analysis and interpretation. 
The chief investigator will notify the RMC in the case 
of AEs and ARs. The principal investigator at each site 
will be the physiotherapist delivering the intervention. 
They will be responsible for recruitment and screening 
participants according to the inclusion and exclusion 
criteria, reporting AEs and ARs and local governance 
requirements.
EthICs And dIssEMInAtIon
Study newsletters will be published by the RMC and 
available on the website of the Haemophilia Society. The 
results of this feasibility study will inform the design of a 
definitive RCT to test whether muscle strengthening can 
benefit musculoskeletal health in children with haemo-
philia, including whether such a study can be achieved 
and the best way of completing it. The results of the feasi-
bility study will be presented at local, national and inter-
national physiotherapy and haemophilia meetings as well 
as manuscripts submitted to peer-reviewed journals. The 
main findings of the study will be shared to all partici-
pants and the Haemophilia Society.
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